Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Biodesix, Inc.
BDSX
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $199.4M
$21.99
▼ -10.24%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$5.26 - $24.92
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 345.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary blood-based diagnostic technology reducing need for invasive procedures
- Clinical validation and regulatory approvals for multiple test panels
- Strategic partnerships with established diagnostics companies (Bio-Rad Laboratories)
- Comprehensive data platform integrating genomic and immunological insights
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Strong growth ahead
Increasing adoption of precision medicine and early cancer detection protocols
Value
Deep value opportunity - significant discount to Life Sciences Tools peers
Momentum
Hot
+62.6% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying BDSX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 6, 2026
MAY 4, 2026
Reported EPS of -$0.81 vs -$1.13 consensus (+28.3% surprise). Revenue of $25.6M vs $23.1M expected (+10.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+28.3%
Next: Aug 6, 2026
Revenue trend · last 8Q
—
—
—
+21%
+12%
+20%
+41%
+42%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$17.9M
$18.2M
$20.4M
$18.0M
$20.0M
$21.8M
$28.8M
$25.6M
Margins · last 8Q
Gross
—
Operating
—
Profit
-30.5%
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Roth Capital · Jun 24, 2026